DIAGNOS Inc. News
-
DIAGNOS Announces the Engagement of Market Maker Consultant
October 17, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Grant of Stock Options
October 03, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Voting Results of Meeting of Shareholders
September 26, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Variation in One Insider Ownership
September 20, 2024 (Source) — In accordance with regulatory requirements, Diagnos Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX…
-
DIAGNOS Announces Closing of Private Placement
September 20, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
August 22, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader…
-
DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
August 20, 2024 (Source) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader…
-
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
June 5, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS celebrates the launch of Labtician’s new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
May 21, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
-
DIAGNOS Announces Closing of First Tranche of Private Placement
May 09, 2024 (Source) — DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer…
